Candidate Clinical Correlate of Prognostic Outcome for TB Study

RecruitingOBSERVATIONAL
Enrollment

750

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Tuberculosis
Interventions
DIAGNOSTIC_TEST

RS ratio

We will evaluate the non-culture, sputum-based assay RS ratio, which measures ongoing Mycobacterium tuberculosis activity by quantifying the abundance of precursor rRNA relative to mature rRNA (an indicator of active rRNA synthesis).

DIAGNOSTIC_TEST

Blood-based host immune response assays

We will evaluate blood-based assays measuring host immune response parameters for predicting mycobacterial activity.

Trial Locations (3)

Unknown

RECRUITING

Kisenyi Health Center, Kampala

RECRUITING

Mulago Outpatient Department, Kampala

NOT_YET_RECRUITING

Hanoi Lung Hospital, Outpatient departments, Hanoi

All Listed Sponsors
collaborator

University of California, Irvine

OTHER

collaborator

University of Colorado, Denver

OTHER

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of California, San Francisco

OTHER

NCT07018076 - Candidate Clinical Correlate of Prognostic Outcome for TB Study | Biotech Hunter | Biotech Hunter